Volume 89 Issue 2 | p. 18 | Concentrates
Issue Date: January 10, 2011

UCB Plans Swiss Biologics Facility

Department: Business
Keywords: contract manufacturing, antibody, microbial expression
UCB is building a biotech drug pilot plant in Braine l’Alleud, Belgium.
Credit: UCB
8902buscon10_live-2
 
UCB is building a biotech drug pilot plant in Braine l’Alleud, Belgium.
Credit: UCB

The Belgian drug company UCB will spend about $330 million to build a microbial manufacturing plant for Cimzia, a monoclonal antibody used to treat Crohn’s disease and rheumatoid arthritis. The company says the plant will open in 2015 at its site in Bulle, Switzerland. It will complement a planned pilot plant in Belgium and contract manufacturing agreements, including one with Lonza. Last month, UCB agreed to sell three pharmaceutical chemical plants in Europe to the contract manufacturer Aesica.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment